Id: | acc0141 |
Group: | 2sens |
Protein: | STAT5 |
Gene Symbol: | STAT5A |
Protein Id: | P42229 |
Protein Name: | STA5A_HUMAN |
PTM: | phosphorylation |
Site: | Tyr694 |
Site Sequence: | PVLAKAVDGYVKPQIKQVVPE |
Disease Category: | Cancer |
Disease: | Leukemia |
Disease Subtype: | CML |
Disease Cellline: | HL-60 |
Disease Info: | |
Drug: | imatinib |
Drug Info: | "Imatinib is a tyrosine kinase inhibitor that targets Bcr-Abl and KIT proteins, used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)." |
Effect: | no effect |
Effect Info: | "AD 198 can bypass the Bcr-Abl anti-apoptotic signal, is cytotoxic to human leukemia cells, and enhances the cytotoxicity of imatinib." |
Note: | |
Score: | 4.5 |
Pubmed(PMID): | 17187856 |
Sentence Index: | 17187856_6-7 |
Sentence: | "Further, AD 198 rapidly induces Erk1/2 and STAT5 phosphorylation prior to cytochrome c release from mitochondria, indicating that proliferative pathways are active even as drug-treated cells undergo apoptosis. At sub-cytotoxic doses, AD 198 and its cellular metabolite, N-benzyladriamycin (AD 288) sensitize CML cells to imatinib through a supra-additive reduction in the level of Bcr-Abl protein expression." |
Sequence & Structure:
MAGWIQAQQLQGDALRQMQVLYGQHFPIEVRHYLAQWIESQPWDAIDLDNPQDRAQATQLLEGLVQELQKKAEHQVGEDGFLLKIKLGHYATQLQKTYDRCPLELVRCIRHILYNEQRLVREANNCSSPAGILVDAMSQKHLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFAQLAQLSPQERLSRETALQQKQVSLEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCEKLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAATVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNECSGEILNNCCVMEYHQATGTLSAHFRNMSLKRIKRADRRGAESVTEEKFTVLFESQFSVGSNELVFQVKTLSLPVVVIVHGSQDHNATATVLWDNAFAEPGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNRENLPGWNYTFWQWFDGVMEVLKKHHKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIAWKFDSPERNLWNLKPFTTRDFSIRSLADRLGDLSYLIYVFPDRPKDEVFSKYYTPVLAKAVDGYVKPQIKQVVPEFVNASADAGGSSATYMDQAPSPAVCPQAPYNMYPQNPDHVLDQDGEFDLDETMDVARHVEELLRRPMDSLDSRLSPPAGLFTSARGSLS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACSTAT5A-Tyr694 | |
---|---|
Cancer | Intensity |
BRCA | -0.21 |
COAD | 0.081 |
HGSC | 2.396 |
ccRCC | 0.242 |
GBM | -0.214 |
HNSC | 0.119 |
LUAD | 0.595 |
LUSC | 0.038 |
non_ccRCC | -1.223 |
PDAC | -0.376 |
UCEC | -1.449 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
Y | 694 | D | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
Y | 694 | D | Sjogren's syndrome | Phosphorylation | 36072585 |
Y | 694 | N | Large granular lymphocytic leukemia | Phosphorylation | 23596048 |
Y | 694 | U | Glioblastoma | Phosphorylation | 22729867 |
Y | 694 | U | Colon cancer | Phosphorylation | 23733954 |
Y | 694 | U | Human immunodeficiency virus infectious disease | Phosphorylation | 21716071 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.